Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
Artif Organs ; 39(4): 352-60, 2015 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-25345752

RESUMEN

Extrahepatic bile duct (EBD) injury can happen during surgery. To repair a defect of the EBD and prevent postoperative biliary complications, a collagen membrane was designed. The collagen material was porous, biocompatible, and degradable and could maintain its shape in bile soaking for about 4 weeks. The goal was to induce rapid bile duct tissue regeneration. Twenty Chinese experimental hybrid pigs were used in this study and divided into a patch group and a control group. A spindle-shaped defect (20 mm × 6 mm) was made in the anterior wall of the lower EBD in the swine model, and then the defect was reconstructed using a collagen patch with a drainage tube and wrapped with greater omentum. Ultrasound was performed at 2, 4, 8, and 12 weeks postoperatively. Liver function tests and white blood cell count (WBC) were measured. Hematoxylin-eosin staining, cytokeratin 7 immunohistochemical staining, and Van Gieson's staining of EBD were used. The diameter and thickness of the EBD at the graft site were measured. There was no significant difference in liver function tests or WBC in the patch group compared with the control group. No evidence of leakage or stricture was observed, but some pigs developed biliary sludge or stone at 4 and 8 weeks. The drainage tube was lost within 12 weeks. The neo-EBD could withstand normal biliary pressure 2 weeks after surgery. Histological study showed the accessory glands and epithelial cells gradually regenerated at graft sites from 4 weeks, with increasing vessel infiltration and decreasing inflammation. The collagen fibers became regular with full coverage of epithelial cells. The statistical analysis of diameter and thickness showed no stricture formation at the graft site, but the EBD wall was slightly thicker than in the normal bile duct due to collagen fiber deposition. The structure of the neo-EBD was similar to that of the normal EBD. The collagen membrane patch associated with a drainage tube and wrapped with greater omentum effectively induced the regeneration of the EBD defect within 12 weeks.


Asunto(s)
Conductos Biliares Extrahepáticos/cirugía , Procedimientos Quirúrgicos del Sistema Biliar/instrumentación , Materiales Biocompatibles , Colágeno , Membranas Artificiales , Procedimientos de Cirugía Plástica/instrumentación , Regeneración , Animales , Conductos Biliares Extrahepáticos/diagnóstico por imagen , Conductos Biliares Extrahepáticos/lesiones , Conductos Biliares Extrahepáticos/patología , Conductos Biliares Extrahepáticos/fisiopatología , Modelos Animales de Enfermedad , Diseño de Equipo , Estudios de Factibilidad , Femenino , Inmunohistoquímica , Recuento de Leucocitos , Pruebas de Función Hepática , Masculino , Epiplón/cirugía , Complicaciones Posoperatorias/etiología , Porcinos , Factores de Tiempo , Ultrasonografía
2.
Zhonghua Nan Ke Xue ; 15(9): 801-5, 2009 Sep.
Artículo en Zh | MEDLINE | ID: mdl-19947562

RESUMEN

OBJECTIVE: The progression of prostate cancer (PCa) after endocrine therapy varies widely in different PCa patients. This study aims to analyze the factors that influence the progression-free survival time of PCa patients after endocrine therapy in an attempt to improve the prognosis of the disease. METHODS: We reviewed the clinicopathological data of 116 cases of prostate cancer treated by endocrine therapy, analyzed the clinicopathological factors that influence the progression-free survival time of PCa patients using univariate (log-rank test) and multivariate Cox proportional hazard models, and investigated the correlation among these factors by Spearman rank correlation analysis. RESULTS: In the stepwise Cox proportional hazard model, the independent prognostic factors for PCa progression after endocrine therapy were found to be Gleason score (P < 0.01) and clinical stages (P < 0.01). The hazard of PCa progression after endocrine therapy increased 2.126 times that of the baseline for each unit of increase in Gleason score, and 6.625 times for each unit of increase in the clinical stage. The pretreatment PSA level was correlated with both clinical stages (P < 0.01) and Gleason score (P < 0.01). CONCLUSION: Clinical stages and Gleason score were important factors that influenced the progression-free survival time after endocrine therapy in this cohort of PCa patients.


Asunto(s)
Próstata/patología , Neoplasias de la Próstata/patología , Neoplasias de la Próstata/terapia , Anciano , Anciano de 80 o más Años , Supervivencia sin Enfermedad , Humanos , Masculino , Persona de Mediana Edad , Estadificación de Neoplasias , Pronóstico , Modelos de Riesgos Proporcionales , Neoplasias de la Próstata/mortalidad
3.
Biomaterials ; 33(17): 4298-308, 2012 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-22429981

RESUMEN

Extrahepatic bile duct defects and their complications are benign lesions but with malignant outcomes. Extrahepatic bile duct regeneration at the injury site could be important for the repair. In our previous work, a human basic fibroblast growth factor (bFGF) fused with a collagen-binding domain (CBD) was produced to activate the collagen membrane to obtain targeted tissue regeneration. This collagen/growth factor functional biomaterial could promote the regeneration of skin, bladder and full-thickness abdominal wall by accelerating vascularization and cellularization of autologous tissues. We speculate that the functional biomaterial could also provide the repairing effect on extrahepatic bile duct injuries. Using a pig extrahepatic bile duct injury model, we found that the collagen/CBD-bFGF composite biomaterial could significantly promote the extrahepatic bile duct regeneration at the injury site without causing structure deformation or hepatic dysfunction during both short- and long-time observations.


Asunto(s)
Conductos Biliares Extrahepáticos/fisiología , Colágeno/farmacología , Factor 2 de Crecimiento de Fibroblastos/farmacología , Regeneración/efectos de los fármacos , Andamios del Tejido/química , Animales , Conductos Biliares Extrahepáticos/diagnóstico por imagen , Conductos Biliares Extrahepáticos/patología , Conductos Biliares Extrahepáticos/cirugía , Bilirrubina/metabolismo , Peso Corporal/efectos de los fármacos , Bovinos , Colangiografía , Colágeno/metabolismo , Colágeno/ultraestructura , Constricción Patológica , Desmina/metabolismo , Factor 2 de Crecimiento de Fibroblastos/metabolismo , Humanos , Implantes Experimentales , Queratina-19/metabolismo , Hígado/efectos de los fármacos , Hígado/enzimología , Pruebas de Función Hepática , Miocitos del Músculo Liso/efectos de los fármacos , Miocitos del Músculo Liso/metabolismo , Neovascularización Fisiológica/efectos de los fármacos , Complicaciones Posoperatorias/etiología , Complicaciones Posoperatorias/patología , Unión Proteica/efectos de los fármacos , Procedimientos de Cirugía Plástica , Coloración y Etiquetado , Sus scrofa , Factores de Tiempo , Factor de von Willebrand/metabolismo
SELECCIÓN DE REFERENCIAS
Detalles de la búsqueda